台灣協和麒麟股份有限公司

Dr. Shibasaburo Kitasato and Dr. Bering discovered that the serum obtained from an animal infected with diphtheria was effective in the treatment of diphtheria and tetanus; they established serum therapy.

Establishment of Kirin Brewery Co., Ltd.

Establishment of Kyowa Hakko Kogyo Co., Ltd. as a secondary company of Kyowa Sangyo Co., Ltd, as part of industrial readjustment plans.

Introduced production technology of Streptomycin, an anti-tubercular drug, from US pharmaceutical company Merck & Co., Inc. and succeeded in its mass production. Contributed to the wiping out of tuberculosis in Japan (beginning of involvement in pharmaceutical business operations).

Success of isolation and commercially mass-production of the anticancer drug, Mitomycin C. Invention of the process of L-glutamic acid production by fermentation (a world first).

Gerald Edelman and Rodney Porter determined the molecular structure of antibodies.

Initiation of full-scale involvement in the pharmaceutical business. Release of Mitomycin C, an anticancer drug, and Spiramycin, an antibiotic drug.

Release of 5-FU, an anticancer drug.

Release of Leunase, an anticancer drug.

César Milstein, Georges Köhler and Niels Kaj Jerne established the hybridoma technology, which is a technology for producing monoclonal antibodies.

Dr. Susumu Tonegawa discovered the genetic principle for the generation of antibody diversity.

The Research Institute for Production Development foundation begins full-scale research towards the commercialization of erythropoietin.

The world's first therapeutic antibody "muromonab" was approved.

Supported the establishment in the U.S.A. of the La Jolla Institute for Allergy and Immunology (LIAI).

Release of ESPO®, an erythropoietin (EPO) drug.

Antibody engineering technologies were established.

Release of GRAN®, G-CSF drug. Release of Coniel, a remedy for hypertension and angina pectoris.

Establishment of fully human antibody production technology.

Establishment of BioWa, Inc. in the United States to promote Kyowa Hakko's therapeutic antibody business.

Japan’s first therapeutic antibody "tocilizumab" was approved.

The launch of Kirin Pharma Company, Limited to accompany the adoption by Kirin Brewery Company, Limited of a pure holding company system. Release of NESP®, a long-acting erythropoietic stimulating drug. Established COMPLEGENT®, a novel antibody engineering technology that enhances the efficacy of antibodies, and licensed to BioWa, Inc, its subsidiary. Capital alliance between Kyowa Hakko Group and Kirin Group.

Release of REGPARA®, a drug for secondary hyperparathyroidism. Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd. Kyowa Hakko Kirin was formed through the merger of Kyowa Hakko Kogyo and Kirin Pharma.

Release of REGPARA®, a drug for secondary hyperparathyroidism. Spun off its biochemical business, establishing Kyowa Hakko Bio Co., Ltd.

Introduced 'Commitment to Life'.

Introduced "Commitment to Life".

Acquired ProStrakan Group plc.

Launch of Poteligeo® in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL).

Launch of NOURIAST® tablets 20 mg in Japan, a novel antiparkinsonian agent.

ProStrakan completes acquisition of Archimedes. Launch of Sustained-Duration G-CSF Product G-LASTA® in Japan.

ProStrakan Completes Acquisition of Archimedes. Launch of Sustained-Duration G-CSF Product G-LASTA® in Japan.

Rebranding Western Pharmaceutical Subsidiaries to 'Kyowa Kirin'. Launch of LUMICEF® for Psoriasis Treatment in Japan.

Rebranding Western Pharmaceutical Subsidiaries to "Kyowa Kirin". Launch of LUMICEF® for Psoriasis Treatment in Japan.

Crysvita® approved in the US and Europe for X-linked hypophosphatemia. Poteligeo® approved in the US and Europe for mycosis fungoides (MF) and Sézary syndrome (SS).

Crysvita® approved in the US and Europe, sales to start as a treatment for patients with X-linked hypophosphatemia. Poteligeo® approved in the US and Europe as a treatment for mycosis fungoides (MF) and Sézary syndrome (SS).

Trade name changed to 'Kyowa Kirin Co., Ltd.' from Kyowa Hakko Kirin Co., Ltd. Crysvita® launched in Japan for FGF23-related Hypophosphatemic Rickets and Osteomalacia. Nourianz™ launched in the US for Parkinson's disease.

Trade name changed to current "Kyowa Kirin Co., Ltd." from Kyowa Hakko Kirin Co., Ltd. Crysvita® launched in Japan for the treatment of FGF23-related Hypophosphatemic Rickets and Osteomalacia. Nourianz™ launched in the US for use in Parkinson's disease.

Poteligeo® launched in Europe for mycosis fungoides (MF) and Sézary syndrome (SS). Crysvita® approved in the US for tumor-induced osteomalacia (TIO).

Poteligeo® launched in Europe for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS). Crysvita® approved in the US for the treatment of tumor-induced osteomalacia (TIO).

New Vision toward 2030. Agreement with Amgen to develop and commercialize KHK4083. Support for TCFD recommendations.

New Vision toward 2030 designed to realize the creation and delivery of life-changing value. Agreement reached with Amgen to jointly develop and commercialize KHK4083, a Kyowa Kirin-discovered anti-OX40 fully human monoclonal antibody. Declared support for the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD).

Global DE&I Statement adopted. Launch of G-Lasta® Subcutaneous Injection 3.6 mg BodyPod in Japan. Completion of Q-TOWER analysis facility at Takasaki Plant.

More than 100 therapeutic antibodies have been approved in Japan, Europe, and the United States.

Global DE&I Statement adopted with 40% of global leaders to be female by 2030. An automated injection device "G-Lasta® Subcutaneous Injection 3.6 mg BodyPod" launched in Japan for the long-acting G-CSF preparation, G-Lasta®. Q-TOWER, the new biopharmaceutical analysis facility completed at Takasaki Plant, Kyowa Kirin's major biopharmaceutical manufacturing site.

PHOZEVEL® approved in Japan for Hyperphosphatemia. Acquisition of Orchard Therapeutics.

PHOZEVEL® approved in Japan for the treatment of Hyperphosphatemia in chronic kidney disease patients. Kyowa Kirin announced the acquisition of UK company Orchard Therapeutics with strength in hematopoietic stem cell gene therapy.

Lenmeldy™ approved and launched in the US. New biologics manufacturing plant planned in North Carolina. Collaboration with Kura Oncology on menin inhibitor ziftomenib.

Lenmeldy™, an innovative hematopoietic stem cell (HSC) gene therapy, approved and launched in the United States. A new biologics manufacturing plant decided to be established in North Carolina, the United States. A global strategic collaboration signed to develop and commercialize menin inhibitor ziftomenib in acute leukemias with Kura Oncology.

Completion of HB7 Building at Takasaki Plant. FDA approval and US launch of KOMZIFTI™ (ziftomenib) for AML.